The treatment (two doses administered on days 0 and 7, respectively) induced a significant targeted effect on both tumor size and the number of uPAR positive cancer cells compared to non-binding analog (177Lu-DOTA-AE105mut) and vehicle control-treated groups [165]. The gene discussed is PLAUR; the disease is cancer.